Price
No data yet.
Social Signal Score
Revenue
$2.45MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kristen Fortney
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.94
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 8.58
Financials
Revenue
$2.45M+68.9%Net Income
$-26.10MEBITDA
$-26.03MFree Cash Flow
$-19.59MEPS (diluted)
$-0.58Shares Outstanding (diluted)
44.84M+31.2%Operating Expenses
$31.78MCash & Debt
$318.75MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.99M | $-80.61M | $-2.24 |
| 2024 | $0.00 | $-71.11M | $-1.98 |
| 2023 | $0.00 | $-63.85M | $-1.87 |
| 2022 | $0.00 | $-39.72M | $-1.16 |
Valuation
BIOAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
105Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Neutral
…GE-102. BGE-102, a best-in-class NLRP3 inhibitor, achieved up to 98% IL-1β suppression and 86% median hsCRP reduction, with Phase 2 topline data expected in H2 2026. BIOA's diversified pipeline includes ophthalmology and apelin-APJ pathway programs, plus partnerships with Novartis and Eli Lilly, supporting long-term optionality.
View source ↗
Earnings
Thu, Nov 5(in 2 months)
Consensus estimate $-0.61 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.58 vs $-0.61beat
- Fri, May 8$-0.52 vs $-0.64beat
- Tue, Mar 24$-0.72 vs $-0.83beat
- Thu, Nov 6$-0.56 vs $-0.67beat
- Wed, Aug 6$-0.60 vs $-0.56miss
- Tue, May 6$-0.36 vs $-0.52beat
Estimates and results for BIOA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BIOA officers and directors.
- Bought
- $28.7m
- Sold
- $7.8m
7 trades
13 trades
- Barton Shanesold
- Barton Shanesold
- Rubin Paul Dsold
- Rubin Paul Dsold
- Rubin Paul Dsold
- Goldstein Dov A Mdsold
- Goldstein Dov A Mdsold
- Goldstein Dov A Mdsold
80 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.